Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

MIV-210 enters phase I study of multiple oral doses

Feb. 11, 2003

Preclinical anti-HIV development candidate presented at medicinal chemistry conference

Feb. 10, 2003

Boehringer Ingelheim initiates phase III RESIST program for tipranavir

Feb. 10, 2003

Atazanavir reported safe and effective in reducing HIV infection

Feb. 10, 2003

Agouron claims new HIV protease inhibitors

Feb. 4, 2003

Ivax to develop immunotoxin to treat HIV

Feb. 3, 2003

Kaleidos's TGF-alpha to be studied for AIDS by NIAID

Jan. 31, 2003

Novel HIV RT inhibitors prepared and tested at Roche

Jan. 29, 2003

AIDS vaccine developed at Emory and NIH enters clinical testing

Jan. 28, 2003

Uniroyal researchers identify novel antiretroviral agents for HIV and HCMV infections

Jan. 23, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...